Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized 13C Pyruvate Imaging in Breast Cancer
NCT03121989Phase 1Withdrawn
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Nov 2017
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [1-13C]pyruvate in breast cancer (2 arms), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Feasibility of acquiring time resolved, 3D 13C pyruvate MR images at 6 months. Planned start Nov 2017; status: withdrawn.
02
Drugs
[1-13C]pyruvate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03121989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121989.